Abiologics

Overview

Abiologics is developing Synteins, a new class of computationally-designed, programmable biologic medicines beyond traditional antibodies, with an initial focus on oncology and immunology; founded by Flagship Pioneering in 2021 (emerged from stealth in July 2024) with academic co-founder Brad Pentelute of MIT.

Key Facts

Sector

Biotech

Focus Areas